WO2025008797 - ORAL COMPOSITIONS COMPRISING TEMOZOLOMIDE OR LENALIDOMIDE
National phase entry:
Publication Number
WO/2025/008797
Publication Date
09.01.2025
International Application No.
PCT/IB2024/056585
International Filing Date
05.07.2024
Title **
[English]
ORAL COMPOSITIONS COMPRISING TEMOZOLOMIDE OR LENALIDOMIDE
[French]
COMPOSITIONS ORALES COMPRENANT DU TÉMOZOLOMIDE OU DU LÉNALIDOMIDE
Applicants **
SHORLA PHARMA LTD
Questum Acceleration Centre
Clonmel
Co. Tipperary, E91 V329, IE
Inventors
CUNNINGHAM, Sharon
Questum Acceleration Centre
Clonmel
Co. Tipperary, E91 V329, IE
RYAN, Orlaith
Questum Acceleration Centre
Clonmel
Co. Tipperary, E91 V329, IE
DELANEY, Denis
Questum Acceleration Centre
Clonmel
Co. Tipperary, E91 V329, IE
CLANCY, Maurice
Questum Acceleration Centre
Clonmel
Co. Tipperary, E91 V329, IE
BAKER, Rod
Bioedge Pharma Consultancy Limited
2 Minton Place, Victoria Road, Bicester
Oxon OX26 6QB, GB
Priority Data
63/525,276
06.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1904 | |
| EPO | Filing, Examination | 12989 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 7310 |
Total: 23368 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides a composition comprising temozolomide or lenalidomide, a medium chain triglyceride such as miglyol, silicon dioxide and a surfactant, wherein the composition optionally comprises an antioxidant and/or a flavoring agent, and wherein the temozolomide composition is a non-aqueous, preservative free suspension. Also provided is a method for treating cancer in a subject, such as a child or a subject suffering dysphagia and/or has difficulty swallowing.[French]
La présente invention concerne une composition comprenant du témozolomide ou du lénalidomide, un triglycéride à chaîne moyenne tel que le miglyol, le dioxyde de silicium et un tensioactif, la composition comprenant éventuellement un antioxydant et/ou un agent aromatisant, et la composition de témozolomide étant une suspension sans conservateur non aqueuse. L'invention concerne également une méthode de traitement du cancer chez un sujet, tel qu'un enfant ou un sujet souffrant de dysphagie et/ou qui présente des difficultés à avaler.